Neurology: Multiple sclerosis, age and contrast enhancement damage are closely related

The disease process of multiple sclerosis (MS) is characterized by inflammation and neurodegeneration
.

Some studies have shown that the frequency of CEL decreases with age.
This finding is consistent with the observation that recurrence decreases with age and the duration of the disease.
It is also consistent with the inflammatory disease activity of MS in young people, and in the elderly.
The more uncommon general views agree
.

They used the original trial data of the CombiRx cohort, namely the RRMS trial, the ASCEND SPMS trial, and the PROMISE and INFORMS trials of primary progressive multiple sclerosis to describe the ages of the entire trial cohort at baseline and one year later in the treatment group.
Group CEL occurrence
.

CombiRx includes 1,008 people, ASCEND 889 people, PROMISE 943 people, and INFORMS 970 people
.

At baseline, the frequency of CEL varies in different data sets due to the disease process
.

This distribution according to the course of the disease remained basically unchanged in each age group
.

In all data sets, the proportion of participants with CELs decreased almost linearly with age
.

After one year of experimental treatment, the incidence of CEL in all experimental data sets has decreased, and there is almost no CEL in ASCEND
.

In all data sets, age is the only feature related to the risk of baseline CELs.
The older the age, the lower the risk of CELs (for each year of increase in age, the odds (OR) of CELs at baseline)
.

The significance of this study lies in the discovery: the analysis of four large, well-characterized RCT data sets shows that age and the occurrence of CEL are a common phenomenon in the entire MS disease process
.